INTEGRATED HEALTH TECHNOLOGIES, INC. ANNOUNCES ACQUISTION OF BIOTECH
        COMPANY THAT DEVELOPS NOVEL PLANT-BASED NUTRACEUTICALS AND DRUGS

   Feasibility Project to Develop a Potent Anti-Cancer Nutritional Supplement
                  Using Genetically Modified Plants Completed

HILLSIDE,  N.J.,  March 5  /PRNewswire/--Integrated  Health  Technologies,  Inc.
(Nasdaq:  IHTC-news) today announced the acquisition of NuCycle Therapy, Inc. of
Monmouth   Junction,   N.J.  This   purchase   accelerates   Integrated   Health
Technologies'  new product  development  efforts in the  nutraceutical  and drug
development  area.   NuCycle  Therapy  is  a  biotechnology   company  utilizing
proprietary processes to develop unique nutritional supplements,  nutraceuticals
and drugs in plants.

Sy Flug,  President of Integrated Health  Technologies,  stated, "Our goal is to
become a world leader in new product  development for  nutritional  supplements,
nutraceuticals and drugs. The announced acquistion significantly strengthens the
technical  capabilities of IHTC and accelerates new product development with the
addition of NuCycle's existing product line of plant-based  mineral  supplements
and a full R&D pipeline of new products in development."

NuCycle Therapy has  demonstrated  the high quality of its existing  nutritional
supplements  through  animal  and  laboratory  testing.   The  Company  is  also
collaborating on clinical trials involving control of blood glucose levels using
its plant based chromium supplements.

The combined entity will continue to focus on developing new products  important
to diet, health and the quality of life.  NuCycle brings an extensive  portfolio
of  intellectual  property  including  issued and pending  patents and  know-how
involving novel nutritional  supplements and nutraceuticals.  Company scientists
are using  entirely  new  methods for  discovering  and  manufacturing  valuable
products from both natural and genetically modified plants.

Burt D. Ensley,  Ph.D. NuCycle's President and CEO, will direct the expanded R&D
efforts of the combined entity. One of the original scientists at Amgen, Inc., a
top global biotechnology company, Dr. Ensley is a leading expert in the field of
biotechnology  and  nutritional  supplements.   He  has  a  Ph.D.  in  Microbial
Physiology and is a Fellow of the American Academy of Microbiology. Dr. Ensley's
research  has  resulted  in the  development  of a number  of  unique  products,
including highly  bio-available and safe  phytomineral  supplements from natural
and genetically  modified plants.  NuCycle has recently  completed a feasibility
demonstration  project  funded by the  National  Cancer  Institute  to produce a
potent  anti-cancer  nutritional  supplement using  genetically  modified plants
(GMO's).  In collaboration with researchers from Northern Arizona University and
Rutgers,  The State University of New Jersey,  as well as the USDA laboratory at
Cornell,  the Company is seeking  National Cancer  Institute  funding to further
develop this sophisticated  technology for the discovery and production of novel
nutraceuticals and drugs.

Integrated Health Technologies, Inc. is a unique grouping of companies presently
serving  the  diversified  needs  of  the  nutraceutical  and  drug  industries:
Manhattan  Drug  Company,  Inc.  provides  contract  manufacturing,  IHT  Health
Products,  Inc. provides raw material sourcing and Integrated Health Ideas, Inc.
provides new product development and technical services.  NuCycle Therapy, Inc.,
utilizing  proprietary  processes,   develops  unique  nutritional  supplements,
nutraceuticals and drugs in plants.

Forward-looking  statements in this release are made pursuant to the safe harbor
provisions  of the  Private  Securities  Litigation  Reform  Act of 1995.  These
forward-looking  statements  are  subject  to  certain  risks and  uncertainties
detailed in the Company's filings with the Securities and Exchange Commission.




Wolfe  Axelrod  Weinberger   Associates  LLC  acts  as  the  company's  investor
relation's  agency and it and/or its employees may have a position in and/or own
warrants or options in the  aforementioned  company.  All information  mentioned
herein has been obtained from sources, which are believed to be reliable, but in
no way guaranteed as to their accuracy or completeness.